1. Volume 17, Issue 2, Pages 245-253 (March 2014)
Policymaker, Please Consider Your Needs Carefully: Does Outcomes Research in Relapsed or Refractory Multiple Myeloma Reduce Policymaker Uncertainty Regarding Value for Money of Bortezomib? 
Margreet G. Franken, MSc, Jennifer G. Gaultney, MPH, MSc, Hedwig M. Blommestein, MSc, Peter C. Huijgens, PhD, MD, Pieter Sonneveld, PhD, MD, William K. Redekop, PhD, Carin A. Uyl-de Groot, PhD 
Value in Health 
Volume 17, Issue 2, Pages (March 2014)
DOI: /j.jval
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1 Flowchart of the patient selection process.
Value in Health  , DOI: ( /j.jval )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Kaplan-Meier OS curves from start of relapsed/refractory treatment stratified by treatment with bortezomib.
Value in Health  , DOI: ( /j.jval )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Kaplan-Meier OS curves from start of relapsed/refractory treatment stratified by treatment with bortezomib, bortezomib treatment line and Hovon50 treatment arm.
Value in Health  , DOI: ( /j.jval )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions